Indacaterol
Indacaterol (pronunciation: in-da-KAT-er-ol) is a long-acting beta-adrenoceptor agonist (LABA) used in the management of chronic obstructive pulmonary disease (COPD). It is marketed under the trade names Onbrez Breezhaler by Novartis and Arcapta Neohaler in the U.S.
Etymology
The term "Indacaterol" is a coined name with no specific etymology. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new drugs.
Pharmacology
Indacaterol works by stimulating the beta-2 adrenergic receptors in the lungs, leading to relaxation of the bronchial smooth muscles. This results in bronchodilation and improved airflow, thereby reducing the symptoms of COPD.
Usage
Indacaterol is used as a maintenance treatment for COPD. It is not intended for the relief of acute bronchospasm or for the treatment of asthma. The recommended dose is one inhalation once daily.
Side Effects
Common side effects of Indacaterol include cough, throat irritation, and headache. Serious side effects may include worsening breathing problems, fast or irregular heartbeat, and high blood pressure.
Related Terms
See Also
External links
- Medical encyclopedia article on Indacaterol
- Wikipedia's article - Indacaterol
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski